ALNY

Alnylam Pharmaceuticals, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

07/30/2026

Business Summary

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

 


Analyze ALNY on TradingView

VALUATION

P/E

68.94

Market Cap ($M USD)

$39.98B

Forward P/E

15.41

PEG

0.04

PRICE TO SALES

9.33

PRICE TO BOOK

37.01

EV / EBITDA

64.45

5-Year Average P/E

Free Cash Flow Yield

1.60%

DCF Value

$-1773.51

Graham Number

$28.12

Price to FCF

62.34

EV to FCF

61.66

Earnings Yield

1.45%

FCF Yield

1.60%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$4.34

Next Year EPS Growth Estimate

$19.43

Next Year Revenue Growth Estimate

$1.17T

Return on Equity (ROE)

98.29%

FREE CASH FLOW

Operating Margin

17.54%

Debt-to-Equity

1.62

Piotroski F-Score

7

Altman Z-Score

6.13

Return on Invested Capital (ROIC)

19.90%

Current Ratio

3.13

Quick Ratio

3.06

Net Debt to EBITDA

-0.71

Interest Coverage

2.66

Gross Profit margin

80.89%

FCF PER SHARE

$4.83

REVENUE PER SHARE

$32.26

Analyze ALNY on TradingView

Gainseekers Quantitative Analysis

Summary

Alnylam Pharmaceuticals presents a perplexing valuation scenario. Despite a staggering market cap, the stock traded well below its DCF value, indicating potential mispricing. The Forward P/E of 15.18 suggests a more reasonable future valuation, contrasting sharply with the current P/E of 67.93. The Altman Z-score of 5.93 indicates robust financial health, while an earnings yield of just 1.47% raises questions about immediate returns. This juxtaposition of safety and growth potential makes it a complex play for investors.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Alnylam is uniquely positioned to leverage AI advancements in drug discovery and development. The industry's rapid adoption of tech innovations enhances its ability to streamline R&D processes. This adaptability could be a significant competitive advantage in the evolving healthcare landscape.

The Bull Case

For the discerning GARP investor, Alnylam offers compelling strengths. With an impressive ROIC of 19.90%, the company demonstrates exceptional capital efficiency. A Piotroski F-Score of 7 signals solid financial health, while a gross profit margin of 80.89% underscores its pricing power. Despite a modest FCF yield, the company's ability to generate cash flow remains a testament to its operational prowess.

The Bear Case

However, Alnylam's valuation multiples raise red flags. A Price/Book ratio of 36.46 and Price/Sales of 9.19 suggest the stock is priced for perfection. The EV to EBITDA of 63.49 further highlights its premium valuation, potentially deterring value investors. Additionally, the stock's proximity to its 52-week high, with a mere 14.32% distance to the low, indicates technical overextension, warranting caution.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$445.67

Institutional Ownership %

1-Year Beta

0.30

Insider Buying % (6 Mo)

Distance to 52-Week High

65.48%

Distance to 52-Week Low

5.07%

EARNINGS SURPRISE %

73.17%

50-DAY SMA

$309.19

200-DAY SMA

$386.28

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.